Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
Status:
Recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess
the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus
placebo plus platinum-based doublet chemotherapy as neoadjuvant/adjuvant therapy in subjects
with resectable stage IIIA and IIIB (N2) NSCLC. Primary study endpoints are MPR rate assessed
by BIPR and EFS assessed by BIRC.